Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects
- Registration Number
- NCT01619345
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This trial is conducted in Europe. The aim of this trial is to investigate whether the volume of water administered with NN9924 affects the anatomical location (stomach or proximal small bowel) of tablet erosion.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 27
Inclusion Criteria
- Good general health
- Body mass index (BMI) of 18.5-30.0 kg/m^2 (both inclusive)
Exclusion Criteria
- Males who are not willing to use two acceptable forms of highly effective contraception
- Participation in another clinical trial within 90 days
- Any chronic disorder or severe disease
- Use of GLP-1 (glucagon-like peptide-1) agonists within 3 months preceding dosing
- Subjects who are smokers
- Subjects who have donated any blood or plasma in the past month or in excess of 500 mL within the 12 weeks preceding screening
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Period 1: NN9924 with 50 mL water semaglutide - Period 2: NN9924 with 240 mL water semaglutide -
- Primary Outcome Measures
Name Time Method Anatomical location (stomach or proximal small bowel) of tablet at complete tablet erosion (CTE) Assessed 0-4 hours post dose
- Secondary Outcome Measures
Name Time Method Area under the NN9924 concentration curve From time 0-24 hours Anatomical location of initial tablet erosion (ITE) Assessed 0-4 hours post dose Time to ITE Assessed 0-4 hours post dose Time to CTE Assessed 0-4 hours post dose